Gagelmann, N, De Witte, M, Peczynski, C, Boreland, W, Broers, A, Jost, E, Kulagin, A, Esquirol, A, Sica, S, Kuball, J, Byrne, J, Bethge, W, Maertens, J, St lzel, F, Forcade, E, Collin, M, Parma, M, Choi, G, Kr ger, N, Corradini, P, Finazzi, MC, Corral, L, Villar, S, Mussetti, A, Bloor, A, Ladetto, M, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. DARATUMUMAB FOR PURE RED CELL APLASIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

G mez, VE, Corral, LL, Mahillo, BA, Mellado, PA, Dom nguez, FMM, G mez, MA, Cant , PA, G mez, JM, Ochando, MT, Borrego, AB, Pinedo, LG, Ripa, MTZ, Vicent, MG, Vallejos, AB, Izquierdo, I, Cadenas, IG, Velao, SR, Musseti, A, Giro, EC, Moraleda, PP, Pascual, GO, Sierra, PAG, Garc a, L, Guti rrez, VG, P rez-Sim n, JA. RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Salas, MQ, Solano, MT, Baile-Gonz lez, M, Acera-G mez, M, Fox, L, del Mar P rez-Artigas, M, Santamar a, A, Quintela-Gonz lez, MDC, S nchez-Salinas, A, Salmer n-Camacho, JM, Illana-Alvaro, V, Abdallahi-Lefdil, Z, Cornago-Navascues, J, Pardo, L, Fern ndez-Luis, S, Vega-Su rez, LP, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Izquierdo-Garc a, I, Gonz lez, SR, Mussetti, A, Lavilla, E, L pez-Marin, J, Cedillo, A, Bento, L, Sureda, A. FRAILTY ASSESSMENT IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-TC). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Fern ndez-Barge, T, Dom nguez-Garcia, JJ, Escamilla, MS, Caballer, JS, Chorao, P, Boluda, JCH, Velao, SR, Cadenas, IG, Bufarull, RM, Estefania, RC, Alexandre, IF, Pe a, AG, Garc a, AT, Ruiz, RG, Luis, SF, San Miguel, EMO, Ara jo, MC, Pell n, SGD, Rodr guez, MAB. OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM-CELL TRANSPLANTATION IN MYELOFIBROSIS: A MULTICENTER STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Salas, MQ, Solano, MT, Baile-Gonzalez, M, Acera-G mez, M, Fox, L, Perez-Artigas, MD, Santamar a, A, Quintela-Gonz lez, MD, S nchez-Salinas, A, Salmer n-Camacho, JM, Illana-Alvaro, V, Abdallahi-Lefdil, Z, Cornago-Navascues, J, Pardo, L, Fern ndez-Luis, S, Vega-Su rez, LP, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Izquierdo-Garc a, I, Rodr guez-Gonz lez, S, Mussetti, A, Abuin-Blanco, A, Lopez-Mar n, J, Filarerro, S, Bento, L, Sureda, A. FRAILTY SYNDROME IN ADULTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-CT). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Bobes, A, Tormo, M, Diaz-Beya, M, Beneit, P, Botella, C, Moreno, AF, Mayol, AS, Sangerman, MA, Bermejo, AY, Amigo, MD, Labrador, J, Guinon, AG, Garrido, A, Serrano, J, Polo, SV, Fortes, MG, Sayas, MJ, Bergua, JM, Olave, MT, Vall-Llovera, F, Bargay, J, Sanchez, MP, Boyero, RG, Diaz-Lopez, A, de la Fuente, A. Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: "Real-Life" Data Versus the RATIFY Study. Clinical Lymphoma Myeloma & Leukemia. 2024; 24DOI:. PMID:. IF:2.700(Q2/4D).